We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Siemens Becomes First Leading Diagnostics Company to Offer Quantitative COVID-19 Test for Measuring Neutralizing Antibodies

By LabMedica International staff writers
Posted on 19 Nov 2020
Print article
Image: Neutralizing antibodies are critical in the fight against COVID-19 because they defend cells from infection by the virus (Photo courtesy of Siemens Healthineers)
Image: Neutralizing antibodies are critical in the fight against COVID-19 because they defend cells from infection by the virus (Photo courtesy of Siemens Healthineers)
Siemens Healthineers’ (Erlangen, Germany) SARS-CoV-2 IgG Antibody Test (sCOVG) has proven to measure neutralizing antibodies and has achieved CE Mark.

The test is an enhanced version of the assay which became available globally this summer, including in the US. It demonstrates the ability to detect neutralizing antibodies and reports quantitative results measuring the amount of neutralizing antibodies present in a patient's blood sample. The company has submitted an application to FDA under Emergency Use Authorization.

Neutralizing antibodies are critical in the fight against COVID-19 because they defend cells from infection by the virus. A virus typically produces an immune response of many antibodies that act as an army to help fight off the virus; however, only a small subset of those antibodies are capable of neutralization—blocking the virus from infecting additional cells. Those neutralizing antibodies develop either in response to natural infection or to vaccination, then subsequently bind to the virus and block infection. To measure a vaccine’s effectiveness, it is critical to identify both the presence of these neutralizing antibodies as well as quantitatively assess the likely level needed to protect against future encounters with the virus. Siemens’ antibody test will make learning this information possible as vaccines are rolled out and exposure to COVID-19 is tested against immunization and the level of immunity a vaccine provides.

Siemens’ SARS-CoV-2 IgG antibody tests are available on one of the largest installed bases of automated immunoassay analyzers worldwide, and the largest in the US. This includes the Atellica Solution and ADVIA Centaur XP and XPT families of analyzers and the Dimension Vista and Dimension EXL systems.

"At the onset of the pandemic, the scientific community had to learn about COVID-19 and how our immune systems would respond. We targeted the spike protein for our antibody tests, anticipating antibodies to this protein would eventually prove to be neutralizing," said Deepak Nath, PhD, President of Laboratory Diagnostics at Siemens Healthineers. "Adequate data is available now to confirm the spike protein antibodies are indeed neutralizing, especially those against the spike receptor binding domain. Healthcare providers can feel confident that our test will help them determine whether a patient's immune system is producing the right antibodies to stop or prevent COVID-19 infection."


New
Gold Supplier
Nucleic Acid Extractor
MGISP-NE384
New
Laboratory Automation System
autioclart
New
SARS-CoV-2 Real-Time RT-PCR Test
GB SARS-CoV-2 Real-Time RT-PCR [E/N/ORF1ab (RdRp)]
New
Silver Supplier
Sample-to-Result COVID Testing Platform
LabTurbo AIO Sample-to-Result COVID Testing Platform

Print article

Channels

Molecular Diagnostics

view channel
Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)

APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.... Read more

Industry

view channel
Illustration

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.